Big Pharma has harsh words for UK's ballooning voluntary reimbursement agreement
In the aftermath of AbbVie and Eli Lilly leaving the UK’s voluntary drug pricing agreement in January, some Big Pharma execs are still raising questions about an agreement that increasingly puts the cost of branded medicines on the companies — as the agreement is set to expire at the end of this year.
The issue revolves around the country’s “Voluntary scheme for branded medicines pricing and access,” or VPAS — an agreement between industry and the UK government signed in 2019 in a bid to keep the prices of certain medications affordable.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.